Grant Award Details
In vivo validation of therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes that incorporate a safety kill switch.
Progress Reports
View Report
Grant Application Details
- Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes
Research Objective
Development of immune tolerant human islet-like organoids for transplantation into diabetic patients.
Impact
Our proposal will progress the development of an unlimited, reproducible source of immune tolerant engineered islets for transplantation into Type I diabetics.
Major Proposed Activities
- Demonstrate efficacy of immune tolerant HILOs in humanized diabetic mice
- Demonstrate safety of immune tolerant HILOs
- Incorporate a “kill switch” into immune tolerant HILOs
Diabetes affects 3 million people in California. Type 1 diabetes is a particular burden as it requires life-long administration of insulin. Allo- transplantation of islets is limited by availability of donor cells. This proposal will progress the development of functional islet-like organoids as an unlimited, reproducible source by engineering in immune tolerance to enhance and prolong functionality and survival upon transplantation into diabetic patients.
Publications
- Nature (2020) Immune-evasive human islet-like organoids ameliorate diabetes. (PubMed: 32814902)